Clinical and pathological stage discordance among 433,514 breast cancer patients

Am J Surg. 2019 Oct;218(4):669-676. doi: 10.1016/j.amjsurg.2019.07.016. Epub 2019 Jul 18.

Abstract

Background: We aim to determine clinical and pathological stage discordance rates and to evaluate factors associated with discordance.

Methods: Adults with clinical stages I-III breast cancer were identified from the National Cancer Data Base. Concordance was defined as cTN = pTN (discordance: cTN≠pTN). Multivariate logistic regression was used to identify factors associated with discordance.

Results: Comparing clinical and pathological stage, 23.1% were downstaged and 8.7% were upstaged. After adjustment, factors associated with downstaging (vs concordance) included grade 3 (OR 10.56, vs grade 1) and HER2-negative (OR 3.79). Factors associated with upstaging (vs concordance) were grade 3 (OR 10.56, vs grade 1), HER2-negative (OR 1.25), and lobular histology (OR 2.47, vs ductal). ER-negative status was associated with stage concordance (vs downstaged or upstaged, OR 0.52 and 0.87).

Conclusions: Among breast cancer patients, nearly one-third exhibit clinical-pathological stage discordance. This high likelihood of discordance is important to consider for counseling and treatment planning.

Keywords: Breast cancer staging; Clinical stage; Pathological stage; Stage discordance.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / therapy
  • Female
  • Humans
  • Logistic Models
  • Male
  • Mastectomy
  • Middle Aged
  • Neoplasm Staging
  • Receptor, ErbB-2
  • Retrospective Studies

Substances

  • Receptor, ErbB-2